UCLA Health will soon begin enrolling for a clinical trial testing whether combining trauma-focused behavioral therapy and MDMA can treat post-traumatic stress in young adults where other treatments have failed.
MDMA is a synthetic, psychoactive controlled substance that induces both stimulant and hallucinogenic effects. MDMA-assisted therapy has been studied in previous clinical trials as a potential treatment for various psychiatric conditions, namely post-traumatic stress disorder (PTSD), However, trials for MDMA-assisted therapy to treat PTSD have mostly consisted of middle-aged and older participants.
The new two-year study will be the first to combine MDMA and trauma-focused cognitive behavioral therapy for adults ages 18-22, also known as transitional age youth, who have treatment-resistant PTSD.
Young adults who have experienced trauma are especially vulnerable to lasting PTSD, and many continue to suffer even after receiving medications and psychotherapy, said lead investigator Dr. Jessica Jeffrey, associate professor of psychiatry at UCLA Health and member of the UCLA Semel Institute for Neuroscience and Human Behavior.
"For a young person whose PTSD hasn’t improved after standard treatment, being told there’s nothing else to try can be devastating,” said Jeffrey. “Studying new options carefully gives these youth and their families a reason to hope.”
The UCLA trial will expand on previous trials of MDMA therapy by pairing the drug with an established, evidence-based therapy of trauma-focused cognitive behavioral therapy. Jeffrey said the expectation is that combining these two approaches may ultimately increase acceptability of the treatment and extend the durability of symptomatic improvements.
Researchers hope this treatment could open a new path for young people whose symptoms have not improved with other treatment approaches and will lay the groundwork for a larger clinical trial.
“Too many young people with PTSD try treatment after treatment without lasting relief,” said Jeffrey, “By pairing MDMA with trauma-focused therapy, we hope to learn whether this approach can offer a safe path toward healing.”
The trial is being funded by a $500,000 grant award from the Ortus Foundation, a non-profit organization focused on improving youth mental health and suicide prevention.
The trial is set to conclude in 2028.
Co-investigators include Dr. Charles Grob, Marc Weintraub and David Miklowitz of UCLA Health.